Table 4.

Multiplex RT-PCR and Cytogenetic Data on 102 AML Patients

UPN3-150Status Sex Age (yr) SampleMultiplex RT-PCR Karyotype
A
   15 Presen. F30 PB t(8;21)(q22;q22) 46,XX,t(8;21)(q22;q22)[5]
   16 Presen. F 18 PB t(8;21)(q22;q22)46,XX[1]/47,XX,ins(1)(q11;?),+mar[5]
   19 Presen.F 2.5 BM t(6;11)(q27;q23) 46,XX[10]
   20Presen. M 68 PB inv(16)(p13;q22)46,XY[2]/46,XY,inv(16)(p13q22)[8]
   22 Presen.M 9 PB t(10;11)(p12;q23)46,XY,t(10;11)(q23;q25)[3]/47,XY,ibid,der(19)t(1;19)(q21;p13 or q13)[9]
   23 Relapse F 38 PBt(6;9)(p23;q34) 46,XX,t(6;9)(p23;q34)[10]
   25Relapse M 43 PB inv(16)(p13;q22)46,XY[4]/46,XY,inv(16)(p13q22)[6]
   29 RelapseM 73 PB t(8;21)(q22;q22)46,XY,t(8;21)(q22;q22)[6]
   31 Presen. M 64PB dupMLL(11q23) Failed
   43 RelapseM 72 PB dupMLL(11q23) Failed
   44Presen. M 84 PB dupMLL(11q23)47,XY,+8[3]/48,XY,+8,+18[7]
   48 Presen. F34 BM t(9;11)(q22;q23) 46,XX[4]
   62Presen. F 24 BM dupMLL(11q23)46,XX[2]
   67 Remis. M 52 PBdupMLL(11q23) 46,XY[1]/46,XY,del(9)(q?31)[4]
   70 Remis. M 60 PB dupMLL(11q23)46,XY[10]
   73 Presen. F 1.0 PBt(10;11)(p12;q23)46,X,der(X)t(X;1)(q13;q12),10,der(11)t(10;11)(q22;q23),+mar[11]
   75 Presen. F 38 BM t(11;19)(q23;p13.1)46,XX,[8]/47,XX,+8[2]
   84 Presen. M 57PB t(15;17)(q21;q22)46,XY[1]/47,XY,+Y[6]/48,XY,+Y,+?21[2]
  137 Presen.M 60 BM dupMLL(11q23) Failed
  181Presen. F 40 PB t(8;21)(q22;q22)46,XX,dup(1)(q21qter),add(14q)[10]
  186 Presen. M41 PB t(8;21)(q22;q22)46,XY,t(3;3)(q26,q29)[8]/47,XY,idem,+21[2]
  192Presen. M 76 PB dupMLL(11q23)46,XY[1]
  208 Presen. F 66 PBt(6;9)(p23;q34) 46,XX[2]
  212 Relapse F 55PB dupMLL(11q23) 47,XX,+83-150[1]
  221Presen. F 44 PB inv(16)(p13;q22) 46,XX[10]
  223 Presen. F 63 PB inv(16)(p13;q22)46,XX[1]
  267 Presen. M 70 PBt(15;17)(q21;q22) 46,XY,t(15;17)(q?22;q11.2)[8]
  342Presen. F 23 PB t(15;17)(q21;q22) 46,XX[10]
 10023-151 Presen. M 69 PB t(15;17)(q21;q22)47,XY,+8[4]/47,XY,+8,del(17)(q?24)[10]
 10043-151 Presen.M 65 PB t(15;17)(q21;q22) 46,XY[5]
B
  18 Presen. M 2.0 PB inv(16)(p13;q22) ND
 118 Presen. M 57 PB inv(16)(p13;q22) ND
 119 Presen. M 77 PB t(15;17)(q21;q22) ND
 122 Presen. F 41 PB t(9;22)(q34;q11) ND
 125 Presen. M 21 PB dupMLL(11q23)ND
 128 Presen. F 55 PB t(8;21)(q22;q22)ND
 129 Presen. M 21 BMdupMLL(11q23) ND
 132 Presen. M 43BM t(8;21)(q22;q22) ND
 145 Presen. F 82PB t(9;22)(q34;q11) ND
 148 Presen. F 59PB t(9;22)(q34;q11) ND
 161 Presen. M 79PB t(15;17)(q21;q22) ND
 172 Presen. F 71PB dupMLL(11q23) ND
 193 Presen. F55 PB t(8;21)(q22;q22) ND
 200 Presen. M33 PB t(6;11)(q27;q23) ND
 240 Remis. M1.0 PB t(2;5)(p23;q35) ND
C
  28Presen. F 38 PB NAD 46,XX[6]
  34Presen. M 75 PB NAD Failed
  36Presen. F 53 PB NAD 46,XX[10]
  39Presen. M 23 PB Ins. N/Q cells46,XY,t(15;17)(q22;q21)[10]
  45 Presen. F 62BM Ins. N/Q cells 46,XX[4]/47-48,X,idic(X),+8[cp.6]
  46 Presen. F 49 PB NAD 46,XX[10]
  47 Presen. M 65 PB NAD 47,XY,+8[10]
  51 Presen. F 83 PB NAD46,XX[7]/48-49,X,−X,+dic(17;17)(p11;p11),+19[cp.3]
  53Presen. F 39 PB NAD 46,XX[10]
  54Presen. F 53 PB NAD 46,XX[10]
  55Presen. M 71 PB NAD46,XY[8]/48,XY,+8,+18[7]
  56 Relapse F 32PB NAD 46,XX[10]
  57 Presen. M 56PB NAD 45,XY,−7[3]
  58 Presen. F 9PB NAD 46,XX[12]/47,XX,+4[5]
  60 Presen.F 43 PB NAD 46,XY[10]
  66 Presen.F 78 PB NAD 46,XX[10]
  71 Presen.F 49 PB NAD 46,XX,der(21)t(?X;21)(q26;q11.2)[10]
  72 Presen. F 65 PB NAD 46,XX[10]
  76 Presen. F 70 PB NAD 46,XX[4]
  79 Presen. M 69 PB NAD 46,XY[12]
  80 Presen. F 48 PB NAD 46,XX[10]
  82 Presen. F 55 PB NAD 46,XX[10]
  83 Presen. F 53 PB NAD 46,XX[10]
  85 Relapse M 71 BM NAD46,XY[2]/45,XY,−7[7]
  86 Remis. M 51PB NAD 46,XY[6]
 144 Presen. F 39 BMNAD 46,XX[8]
 146 Presen. M 63 PBNAD 46,XY[10]
 150 Presen. F 63 PBIns, N/Q cells 46,XX[10]
 179 Presen. M 63PB NAD 47,XY,+8[6]
 183 Presen. M 74PB NAD 46,XY[5]
 184 Presen. M 42 BMNAD 46,XY[10]
 185 Presen. M 73 PBNAD 46,XY[3]
 190 Presen. M 75 PBNAD 46,XX[3] 46,XX,5q-[2]
 195 Presen. F68 PB NAD 47,XX,+4[2]
 201 Presen. M48 PB NAD 46,XY[10]
 210 Presen. M47 PB NAD 46,XY[11]
D
  30 Presen.F 71 PB NAD ND
  33 Presen. M 74PB Ins. N/Q cells ND
  78 Presen. M 78BM NAD ND
  87 Presen. M 76 PBNAD ND
 116 Presen. F 38 PB NAD ND
 130 Presen. F 72 PB NAD ND
 131Presen. F 38 BM NAD ND
 133 Presen.F 35 PB Ins. N/Q cells ND
 136 Presen.F 75 PB Ins. N/Q cells ND
 140 Presen.F 47 PB Ins. N/Q cells ND
 141 Presen.F 82 BM NAD ND
 153 Presen. F 36PB NAD ND
 155 Presen. M 78 PB NADND
 158 Presen. F 80 BM Ins. N/Q cellsND
 159 Presen. M 77 PB NAD ND
 160 Presen. F 76 BM NAD ND
 164Presen. M 22 PB NAD ND
 169 Presen.F 75 BM NAD ND
 170 Presen. M 57PB NAD ND
 171 Presen. M 79 BM NADND
 178 Presen. F 56 PB NAD ND
  • (A) PCR-positive patients with cytogenetic data; (B) PCR-positive patients with no cytogenetic data; (C) PCR-negative patients with cytogenetic data; (D) PCR-negative patients with no cytogenetic data.

  • Abbreviations: Presen., presentation; Remis., remission; PB, peripheral blood; BM, bone marrow; NAD, no abnormality detected; Ins. N/Q cells, insufficient number or quality of cells; ND, not done.

  • F3-150 Patients for whom both PB and BM samples were analyzed, only 1 has been included in the table.

  • F3-151 RNA was purified at Aarhus University Hospital before this study.